Vaccination against coronavirus disease 2019 in patients with pulmonary hypertension: a national prospective cohort study

CONCLUSIONS: COVID-19 vaccination did not significantly augment the PH-related major adverse events for patients with WHO groups 1 and 4 PH, although there were some tolerable side effects. A large-scale randomized controlled trial is warranted to confirm this finding. The final approval of the COVID-19 vaccination for patients with PH as a public health strategy is promising.PMID:37439342 | DOI:10.1097/CM9.0000000000002767

Source: Chinese Medical Journal - July 13, 2023 Category: General Medicine Authors: Xiaohan Wu Jingyi Li Jieling Ma Qianqian Liu Lan Wang Yongjian Zhu Yue Cui Anyi Wang Cenjin Wen Luhong Qiu Yinjian Yang Dan Lu Xiqi Xu Xijie Zhu Chunyan Cheng Duolao Wang Zhicheng Jing Source Type: research